Table 1 Therapeutic fusion proteins based on ELPs discussed in this review

IFN-ELP₉₀

45.3

8.6

IFN

Inhibit tumor growth.

Prolong the survival time of mice.

No hemolysis.

[48]

IFN-ELP(V)₉₀

37

280 ± 0.5

IFN

Stimulate anti-tumor immune response,

Inhibit the recurrence of glioblastoma.

[49]

IFN-α-MMPs-ELP(V)₉₀

< 37

422.2 ± 13.7

IFN-α

Improve anti-tumor efficacy.

Increase intratumoral accumulation.

[50]

α-FLT3-ELP(A) ₁₉₂

42.3

14.7

α-FLT3

The fusion protein has high stability and specificity,

Effective therapeutic effect on AML.

[51]

α-CD99-ELP(A)₁₉₂

45.3

15.8

α-CD99

Reduces cell viability of AML cell lines,

Reduced leukemia burden in mice.

[52]

DRA-ELP(V)₁₂₀

25

-

DRA

Eliminate DRA-sensitive tumor tissue

[55]

mini cry -ELP(S)₄₈(I)₄₈

30

2.8

mini cry

Inhibit RPE apoptosis and caspase-3 activation and protect the retina from cell death.

[57]

FGF-21-ELP₁₂₀

~ 30

16.6 ± 3.9

FGF-21

 A single injection can control blood sugar for 5 days.

[59]

vRAGE-ELP(V₄₀C₂)

30

-

vRAGE

Reduce expression of pro-inflammatory factors,

Accelerate wound healing in mice.

[61]